Deported family of 11-year-old U.S. citizen recovering from rare brain tumor requests humanitarian parole
An 11-year-old girl who is a U.S. citizen and is recovering from a rare brain tumor has been living in Mexico since immigration authorities removed her from Texas when they deported her undocumented parents four months ago.
Four of her siblings, three of whom are also U.S. citizens, were also sent to Mexico with the parents.
Since then, the girl's health condition has not improved, her mother told NBC News. In an attempt to return to the United States to get her the care she needs, the family applied for humanitarian parole with U.S. Citizenship and Immigration Services (USCIS) on Thursday.
'We're fighting for my girl's life," the mother said, adding that her daughter isn't recovering from "just any disease. ... She is not going to be cured overnight; it's something that takes time.'
Their request is for the undocumented parents and the girl's noncitizen sibling to be allowed to enter and live in the U.S. temporarily, so that the ailing girl can have "the full support of her family as she gets treatment to help save her life,' said Danny Woodward of the Texas Civil Rights Project, a legal advocacy organization representing the family.
The mother said her daughter's headaches and dizziness have worsened. The symptoms have become so recurrent that the girl's parents spend sleepless nights taking turns monitoring and caring for her.
'She is very scared,' mother said. "We want to be there for her, we want to take care of her 100% like we've been doing so far. We don't want to be separated from her for even a minute."
When the girl was in the U.S., under the care of doctors in Houston "who saved her life," the parents were instructed to rush her to the hospital for an emergency check-up whenever she felt these symptoms, the mother said.
"But out here, that is impossible," she said in Spanish from Mexico, where her family was deported to Monterrey, an area known for the kidnapping of U.S. citizens. 'Where am I going to go?"
NBC News is not publishing the family members' names out of concerns for their safety.
Medical records show the child underwent surgery last year to remove a brain tumor caused by an 'unnamed 'novel' condition,' according to Woodward. This means that few medical specialists can effectively treat and monitor her.
The mother said the girl's doctors in the U.S. were not just treating her daughter's illness; they were "also studying it because they don't know what caused it, why it was so aggressive." Even from Mexico, she has been in touch with the girl's doctors in the U.S., but they can't really assess what's happening to her from afar.
The surgery that saved her life last year did leave the girl with some lasting side effects. The swelling on her brain is still not fully gone, causing difficulties with speech and mobility of the right side of her body as well as memory problems. These require the girl to routinely checking in with doctors monitoring her recovery, get MRI scans every three months, attend rehabilitation therapy sessions and take medication to prevent seizures.
But she has not been able to consistently access this care since the family was deported, her mother and attorney said.
The mother insists that the rod fixator preventing her daughter's right foot from turning inward needs to be replaced, as the girl trips more than usual.
Her seizure medication is being sent to her from the United States because the family can't find the exact one she needs in Mexico, Woodward said. MRIs have also "turned out to be very expensive and challenging for the family to get in Mexico.'
The girl has only been able to get one medical checkup and MRI in Monterrey. The experience made the mother realize how difficult it would be to get a new doctor in Mexico who can get up to speed with her daughter's medical history and treat her illness.
'Not any doctor wants to take on such a huge commitment,' the mother said. "It's like starting from scratch, or worse."
Additionally, 'the stress of the whole situation has definitely played a negative role' in the girl's recovery, Woodward said. 'This family has been severely traumatized."
On Feb. 3, the family was driving from the Rio Grande Valley area, where they lived, to Houston, where the girl's doctors are based, for an emergency medical checkup.
On the way, they stopped at a stateside immigration checkpoint, one they have passed through multiple times. But this time, immigration authorities arrested the parents after they were unable to show legal immigration documentation. Five of their children, ages 15, 13, 11, 8 and 6, were with them when they were arrested.
Woodward said the parents have never done anything to make them a priority for removal. The entire family was taken to a detention facility, where they spent 24 hours before they were placed in a van and dropped on the Mexico side of a Texas bridge on Feb. 4.
"Another layer of this is the fact that the parents were never even given their due process rights, so they never were allowed to go in front of an immigration judge to plead their case," said Rochelle Garza, president of the Texas Civil Rights Project.
A spokesperson for the Department of Homeland Security, which oversees USCIS, previously told NBC News that reports of the family's situation are 'inaccurate' and declined to speak on the specifics of the case, citing privacy reasons. They said in a statement that when 'someone is given expedited removal orders and chooses to disregard them, they will face the consequences.'
The eldest son, an 18-year-old U.S. citizen, was left behind in the U.S.
"The older boy woke up one morning and learned that his entire family was gone," Woodward said. He graduated high school alone, without his family.
'It breaks our hearts,' the mother said as she wept, adding that her son dreams of going to college and becoming a neurosurgeon after seeing how doctors saved his sister's life, but 'he can't do that alone. He needs our support — even though we talk to him every day, it's really hard to be away."
Instead of going to college, her son is working a fast-food job, hoping to soon see his family return home.
While the Trump administration has aggressively stepped up the pace of deportations, including for immigrants who don't have criminal charges or convictions against them, there are three recent cases giving the girl's family hope.
A Mexican mother living in California and her 4-year-old girl, who suffers from a life-threatening intestinal illness, were granted humanitarian parole this month following a public plea for deportation relief. In April, a Venezuelan immigrant in Chicago was released from immigration detention under humanitarian parole to serve as an organ donor for his ailing brother. In March, an undocumented mother in California caring for her 21-year-old daughter, a U.S. citizen undergoing treatment for bone cancer, was detained by immigration authorities and later released "for humanitarian reasons."
Even though the relatives in these cases were not deported, Woodward said, "I don't think that should make any difference from the perspective of the federal government."
"It's a discretionary choice for them to make," he said. "Our case, I think, it's a very strong one for humanitarian parole."
The family's parole application includes letters of support from several members of Congress, including Democratic Reps. Adriano Espaillat of New York and Sylvia Garcia and Joaquin Castro of Texas, all of whom met with the family in Mexico last month.
"We want them to give us that chance," the mother said. "We are not criminals. We are not delinquents. We simply want to save our daughter."
This article was originally published on NBCNews.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Newsweek
12 hours ago
- Newsweek
Exclusive: We Thought Having a Baby Was 'Impossible.' Then Doctors Used AI
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. The parents of the world's first baby born thanks to AI exclusively told Newsweek how a new IVF procedure powered entirely by artificial intelligence made the "impossible" a reality. The couple's hopes of starting a family were crushed when Edna, 42, and Tony, 45, were diagnosed with infertility issues, including Edna's ovarian insufficiency. But in 2023, they were introduced to a prototype study led by Conceivable Life Sciences through Hope IVF—a private clinic in Mexico City. From left to right: Luis, Dr Luis Miguel Campos (the patients' clinician), parents Edna and Tony. From left to right: Luis, Dr Luis Miguel Campos (the patients' clinician), parents Edna and Tony. Conceivable The precision of AI This study proved it was possible to control robotics within the IVF lab to perform ICSI, otherwise known as Intracytoplasmic Sperm Injection, remotely to create an embryo. This means embryos created through the robotic ICSI step receive consistent treatment with high precision and a more controlled approach to combining the egg and sperm, compared to current manual methods. The surgeon still oversees the robot and the processes, but with much improved outcomes. Edna and Tony—who are using their middle names for privacy—spoke exclusively to Newsweek about how they became the first family shaped by AI. "We represent expectations and hope for all those couples who are unable to reach their goal to become parents," they said through Spanish translation. "Once we heard the baby's heartbeat, we felt like we reached something that seemed previously impossible." A scalable model for fertility treatment The prototype study involved 41 patients and to date, has resulted in 21 pregnancies and 18 live births. Its system sees AI-powered robots help human doctors in a first step towards automating IVF treatments. The remote ICSI procedure used allows for a much gentler approach to embryo creation, helping improve quality outcomes at a microscopic level. Baby Luis (his real name) was born in Morelia in November 2024. Now seven-months-old, he has become the first baby to be conceived thanks to AI. Inside the AI system Chief medical officer at Conceivable Life Sciences, Dr. Alejandro Chavez-Badiola and one of the principal investigators on the paper, shared two scenarios: "Am I the lucky patient who is going to be treated by the best embryologist in the world at 8 a.m. after a cup of coffee and with a smile on their face, fully focused," he told Newsweek. "Or am I going to be the unlucky patient who is going to be treated by the best embryologist in the world at 1 p.m. when they're about to inject their 17th egg, thinking about lunch and having just received a distressing phone call from their partner." With this new system, the entire procedure uses mathematical algorithms and robotics to carry out the fertilization process step-by-step, with future precision likely to be beyond human capability. "Automation is not only allowing us to standardize these issues with the precision of robots, but to scale this [and] to make sure that every patient anywhere in the world, at any given time, can be treated by the best embryologists," Dr. Chavez-Badiola said. Remote ICSI photography. Remote ICSI photography. Conceivable Tony told Newsweek that the couple didn't have concerns about using the technology to finally become parents. "Although it can be directed to other purposes like weapons or other negative aspects, I feel like it should be applied on a daily basis, because well done, its purpose will be at the service of mankind," he said. While there will always be a clinical team overseeing the automated lab, remote control enables global teams to manage automated labs beyond regular hours, allowing for 18–20-hour workdays. Additionally, as the system can be operated remotely, a specialist in one country can carry out fertilization procedures for patients in another. Cost and duration were also differing factors from traditional methods, but the couple put their trust in the team at Conceivable. "By being more optimal and efficient, I feel like it will reduce the amount of attempts and the necessity of medications," Edna told Newsweek. Edna said that the process was fraught with emotion, given the negative outcomes of their previous IVF rounds. Edna was working in another city when she took the pregnancy test. "When I told Tony the news I was pregnant, it was a delightful surprise for him," she told Newsweek. "We were very happy." Luis, the first baby born from remote ICSI. Luis, the first baby born from remote ICSI. Conceivable The success rate of 51 percent aligns with industry standards, according to the Vienna Consensus. However, in their trials, the researchers also found that embryos created using this AI system had an as good—if not better—development potential than those made by humans alone, resulting in high-quality blastocysts—the stage at which embryos are typically relocated from an embryo transfer catheter to the uterus. Edna and Tony's clinician Dr. Luis Miguel Campos told Newsweek that once he had explained the process of ICSI to them, they saw it as an opportunity. "I joined this program to help two beautiful humans achieve their when they heard they were pregnant, I cried like never before," he said. As for next steps at Conceivable, Dr. Campos said consistency in outcomes is a top priority, eventually leading to an improvement in access for any patient around the world. "By [producing] consistency in results, the control process will imply reducing costs and be more efficient," he said. Ethics and AI Dr. Alexander Kotlyar, a reproductive endocrinologist and infertility specialist at Genesis Fertility, told Newsweek emerging AI tools in fertility can enhance core ethical principles, provided they are carefully assessed and properly trained. "The ethical debate around AI reminds me of the long-standing tug-of-war behind genetic testing of embryos," he said. "In both cases, there is concern about how the use of new technology, like DNA testing techniques, can truly benefit patient outcomes, [for example], getting pregnant and having a live birth." Dr. Kotlyar explained the use of AI in the fertility field has grown significantly since the first "test tube" baby was born over forty years ago. This development can be partly attributed to the fact that the processes behind AI algorithms are often not transparent, which raises questions about their outcomes and reliability. "This concern is even more profound with AI since decision-making is, at least partly, given to a machine," he told Newsweek. "However, I would reassure patients and the public that in both cases, the technology is always tested against the principles of core medical ethics and if we cannot stay true to those principles, then we do not use the technology." Hope for future parents For Edna and Tony, being the first successful participants of the prototype clinical trial is a dream come true. "We were fortunate to be selected over other candidates for this first treatment, and we feel blessed," they told Newsweek. "We encourage all those couples who are on the journey to becoming parents to not abandon their dreams and hopes." The couple received strong support from both sides of their families. "Some of them felt a little concerned but in the end, everyone was really happy for our outcome," Tony said. When he's old enough, both Edna and Tony will happily tell Luis that he was conceived using AI. "There's a lot of ignorance and certain concerns about technology, but we will explain gladly to our son." Do you have a tip on a health story that Newsweek should be covering? Do you have a question about IVF? Let us know via health@ Reference Mendizabal-Ruiz, G., Chavez-Badiola, A., Hernández-Morales, E., Valencia-Murillo, R., Ocegueda-Hernández, V., Costa-Borges, N., Mestres, E., Acacio, M., Matia-Algué, Q., Farías, A. F.-S., Carreon, D. S. M., Barragan, C., Silvestri, G., Martinez-Alvarado, A., Olmedo, L. M. C., Aguilar, A. V., Sánchez-González, D. J., Murray, A., Alikani, M., & Cohen, J. (2025). A digitally controlled, remotely operated ICSI system: Case report of the first live birth. Reproductive BioMedicine Online, 50(5).
Medscape
a day ago
- Medscape
AI Enhances Prostate Cancer Detection in MRI Analysis
TOPLINE: In a large-scale diagnostic study, artificial intelligence (AI) assistance led to a superior improvement in prostate cancer detection on MRI, increasing diagnostic accuracy by 3.3% compared with unassisted readings. AI support enhanced both sensitivity (96.8%) and specificity (50.1%) at detecting clinically significant prostate cancer (csPCa). METHODOLOGY: Researchers conducted a diagnostic observer study in which 61 readers (34 experts and 27 non-experts) across 17 countries assessed 360 MRI examinations of men with prostate cancer (n = 360; median age, 65 years) with and without AI assistance. The AI system used in this study was curated and developed within the international Prostate Imaging-Cancer AI (PI-CAI) Consortium for the detection and diagnosis of csPCa. The primary objective was to assess whether AI-assisted csPCa diagnosis was superior to unassisted diagnosis at the patient level using the area under the receiver operating characteristic curve (AUROC), sensitivity, and specificity at a Prostate Imaging Reporting and Data System threshold of 3 or more. TAKEAWAY: Among 360 men who were examined, 122 harboured csPCa. The AUROC was 0.916 with AI assistance vs 0.882 without, showing an improvement of 3.3% (P < .001). The sensitivity was 96.8% for AI-assisted assessments vs 94.3% for unassisted assessments, showing a significant improvement of 2.5% (P < .001). Likewise, the specificity was 50.1% for AI-assisted vs 46.7% for unassisted assessments, showing an improvement of 3.4%. Non-expert readers showed greater performance improvement with AI assistance than expert readers, achieving higher AUROC scores than those of unassisted experts. IN PRACTICE: "The findings of this diagnostic study suggest the potential of AI assistance in improving csPCa diagnosis when compared with unassisted assessments of biparametric MRI, with statistically significant improvements observed across AUROC, sensitivity, and specificity at a PI-RADS [Prostate Imaging Reporting and Data System] score of 3 or more. Notably, nonexpert readers demonstrated higher benefits from AI assistance compared with expert readers," the authors wrote. SOURCE: This study was led by Jasper J. Twilt, MSc, Minimally Invasive Image-Guided Intervention Center, Department of Medical Imaging, Radboud University Medical Center, Nijmegen, the Netherlands. It was published online on June 13, 2025, in JAMA Network Open. LIMITATIONS: The data included were retrospectively curated within the scope of PI-CAI, resulting in a mix of consecutive and sampled cohorts. The study's generalisability requires further validation across external cohorts with varying disease prevalence, image quality, and other clinical factors. The controlled online reading workstation environment differed from readers' native settings, potentially affecting diagnostic performance. This study did not assess workflow efficiency or the clinical applicability of performance improvements in real clinical settings. DISCLOSURES: This study received funding support from Health-Holland and the European Union's Horizon 2020. Several authors reported receiving personal fees and research funding and having other ties with various sources. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Medscape
a day ago
- Medscape
First Scan for Suspected AxSpA: X-rays, MRI, or CT?
BARCELONA, Spain — Data from a prospective imaging study question the use of x-ray radiography first in the diagnostic workup of patients with suspected axial spondyloarthritis (axSpA), a practice that is currently a part of recommendations by the European Alliance of Associations for Rheumatology (EULAR). The study, which evaluated three different imaging pathways based on whether x-ray radiography, MRI, or CT of the sacroiliac joint (SIJ) was used first, found that the two latter approaches yielded a higher diagnostic efficacy than the radiograph-first approach. While just 13% of 30 people who were in the radiograph-first arm of the study were confirmed as having axSpA after the initial scan, 22% of 91 patients in the MRI-first and 30% of 84 people in the CT-first arms were given an axSpA diagnosis. X-ray, MRI, or CT first? Dominik Deppe, MD 'To x-ray or not to x-ray? What may sound somewhat philosophical, is a relevant question,' said study investigator Dominik Deppe, MD, who presented the findings at European Alliance of Associations for Rheumatology (EULAR) 2025 Annual Meeting. Deppe, a doctoral student in the Department of Radiology at Charité – Universitätsmedizin Berlin, Berlin, Germany, explained that although radiographs could show certain structural lesions, such as erosions, sclerosis, or ankylosis, and used relatively low levels of radiation, interpretation could be problematic. 'Even among experts, inter-reader reliability remains low,' Deppe said. MRIs are often performed if the results on radiography are negative or inconclusive. Such scans provide additional insights, he added, and can show both structural and inflammatory lesions, such as bone marrow edema. However, the high cost and low availability of MRI relative to radiography, however, were issues, he acknowledged. This is where CT could perhaps prove most useful. Although it's not part of the standard imaging pathway as yet, it is 'a gold standard for structural lesions,' Deppe said. He added: 'Historically, CT is considered to have high radiation exposure, but nowadays, we can perform CT with ultra-low dose techniques that allow us to reduce radiation exposure to a level that is comparable, or even less, compared to conventional x-rays.' Strategies Compared and Results The study included 205 people with suspected axSpA, who were randomly allocated into one of three arms: 30 to a radiograph-first or 'standard' arm, 91 to an MRI-first arm, and 84 to a CT-first arm. Scans were designated positive or negative by the consensus of two specialized musculoskeletal radiologists who were blinded to the clinical data. A positive result was defined as clear signs of structural or inflammation suggestive of axSpA and no further imaging was done. Those with negative scans underwent a subsequent scan with another method; those in the radiograph-first arm had an MRI scan and then a CT scan, those in the MRI-first arm had a CT scan, and those in the CT-first arm had an MRI scan. The results are preliminary because the study is ongoing and results from the final diagnosis by a rheumatologist are not yet available, Deppe said. He reported that in the radiograph-first arm, 26 (87%) people had a negative scan and then had an MRI scan. This was positive in three (11%) and negative in 23 (88%) of people. None of the people with a negative MRI scan had a positive CT scan. In the MRI-first arm, scans were positive in 20 (22%) and negative in 71 (78%) of people. Again, CT added no further cases among the people who were also MRI-negative. Finally, in the CT-first arm, there were 25 (30%) positive and 59 (70%) negative scans. MRI performed in the CT-negative patients detected two (3%) additional cases of confirmed axSpA. Deppe said: 'Our standard approach, [which] we're using right now, has the lowest diagnostic efficacy, compared to the MRI-first and CT-first approach.' Patient Characteristics Information about patient demographics were not presented, however, which prompted Uta Kiltz, MD, a senior rheumatologist at Rheumazentrum Ruhrgebiet, Herne, Germany, to ask for clarification and about the study design. 'Can you give some information about the population you included in the study?' she asked. 'I think we need to have some more context about the decision-making process to really understand the results.' Deppe responded that the patients had been referred with the suspicion and not confirmed diagnosis of axSpA and had been randomized through a third party into the three different imaging arms. Topline patient demographics had been given in the abstract, which stated that the mean age of the population studied was 38 years (SD, 10.58 years) and just over half (58%) were women. Around half (53%) of the study population was HLA-B27 positive. The mean C-reactive protein level was 3.66 mg/L, and the mean BMI was 25.57. The mean duration of back pain was around 8 years, and 70.6% of people had signs of inflammatory back pain. Questions Raised Several discussants raised concerns about the study design and the interpretation of these early findings. Eric Ruderman, MD, of Northwestern University Feinberg School of Medicine, Chicago, questioned why all patients did not receive all three imaging modalities: 'Ultimately, you don't know the diagnostic specificity of the [ultra] low-dose CT. Why didn't you do all three images in each patient, so that you can actually make a comparison once you have the confirmed diagnosis?' Deppe replied that the team wanted to be pragmatic: 'We wanted to evaluate the clinical settings where the patient does not undergo every imaging, but if we found positive results, as in the clinical practice, we don't need further imaging, and this is something we want to demonstrate in the study.' Xenofon Baraliakos, MD, head of rheumatology at the Rheumazentrum Ruhrgebiet, and the new president of EULAR, raised concerns about potential false positives: 'What happens if the x-ray is it was falsely positive? Have you been able to check for that?' Deppe acknowledged the limitation: 'I think this is something we have to do when we have the final diagnosis by the rheumatologist, to see whether we missed or misinterpreted some of the images.' This study was independently supported. Deppe had no conflicts of interest. The commentators were not involved in the study.
